ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis.

Sai MaChen-Chen LuLi-Yan YangJuan-Juan WangBo-Shi WangHong-Qing CaiJia-Jie HaoXin XuYan CaiYu ZhangMing-Rong Wang

Published in: Journal of experimental & clinical cancer research : CR (2018)

This study provides evidence that highly expressed p-ANXA2 (Tyr23) contributes to ESCC progression by promoting migration, invasion and metastasis, and suggests that targeting the SRC-ANXA2-MYC-HIF1A-MYC axis may be an efficient strategy for ESCC treatment.

Keyphrases

transcription factor
endothelial cells
signaling pathway
vascular endothelial growth factor
tyrosine kinase
cell migration
combination therapy
drug delivery
smoking cessation